Short term study of sucrose polyester a nonabsorbable fat-like material as a dietary agent for lowering plasma cholesterol
Open Access
- 1 November 1976
- journal article
- research article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 29 (11) , 1204-1215
- https://doi.org/10.1093/ajcn/29.11.1204
Abstract
The efficacy, safety, and acceptability of sucrose polyester (SPE), a fat-like material that is neither digested nor absorbed, were assessed in 13 normal and seven hypercholesterolemic subjects for its potential as a cholesterol-lowering agent. Addition or substitution of SPE for culinary fats in the diets of the normocholesterolemic individuals produced a mean reduction of total and low-density lipoprotein cholesterol of 14 and 17%, respectively (P < 0.001), despite the daily ingestion of a diet containing 800 mg of cholesterol and of dietary fat with a P/S ratio of 0.4. Total and low-density lipoprotein cholesterol were not significantly reduced by similar 10-day feeding periods of SPE in seven subjects with familial hypercholesterolemia. High-density lipoprotein cholesterol and triglycerides were not changed in normal or hypercholesterolemic subjects receiving SPE. Plasma vitamin A and E levels were reduced by 10 and 21% (p < 0.02 and < 0.001) in both normal and hypercholesterolemic subjects on SPE. These returned to the basal levels when SPE consumption was discontinued. SPE was recovered quantitatively (>97%) in the stools, with the last measurable SPE being found day 3 to 5 after cessation of SPE intake. Despite recovery of 50 g or more of unhydrolyzed SPE in stools during SPE feeding, there was no clinical or chemical steatorrhea. On subtracting SPE's input to total stool fatty acids, it was found that “non-SPE” fatty acids in the stool had not increased during SPE feeding, SPE was easily incorporated into routine foodstuffs in addition to, or in substitution for, conventional dietary fats. On the basis of this short term evaluation in humans and other investigations with the rat and dog, SPE appears to have potential as a cholesterol-lowering agent.This publication has 15 references indexed in Scilit:
- Coronary Artery Disease in 116 Kindred with Familial Type II HyperlipoproteinemiaCirculation, 1974
- Colestipol and Cholestyramine ResinPublished by American Medical Association (AMA) ,1972
- Dietary and Drug Treatment of Primary HyperlipoproteinemiaAnnals of Internal Medicine, 1972
- Prevalence of Plasma Lipoprotein Abnormalities in a Free-Living Population of the Central Valley, CaliforniaCirculation, 1972
- Long-Term Treatment of Hyperlipidemic Patients With ClofibratePublished by American Medical Association (AMA) ,1971
- Effects of colestipol (U-26,597A), a new bile acid sequestrant, on serum lipids in experimental animals and manAtherosclerosis, 1970
- The effects of unsaturated dietary fats on absorption, excretion, synthesis, and distribution of cholesterol in manJournal of Clinical Investigation, 1970
- Long-Term Reduction of Serum Cholesterol Levels of Patients with Atherosclerosis by Small Doses of NeomycinCirculation, 1967
- Effect of Neomycin, Para-Aminosalicylic-Acid and Other Antibacterial Drugs on Serum Cholesterol Level of ManExperimental Biology and Medicine, 1959
- The Effect of Beta Sitosterol on the Serum Lipids of Young Men with Arteriosclerotic Heart DiseaseCirculation, 1956